KALARIS THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
KALARIS THERAPEUTICS, INC. (KLRS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 63.99 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-05
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 63.99M shares, a 2.89% increase year-over-year.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 63.36M shares, a 2.19% increase year-over-year.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 62.96M shares, a 55.59% increase year-over-year.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 62.34M shares, a 2274.45% increase year-over-year.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 62.78M shares, a 133.41% increase from fiscal 2020.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 26.90M shares, a 1991.66% increase from fiscal 2019.
- KALARIS THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 1.29M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 63.99M shares 10-Q · filed 2022-05-05 | 63.68M shares derived: average of 2 quarters · filed 2022-05-05 | 63.44M shares derived: average of 3 quarters · filed 2022-05-05 | 63.17M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 63.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | 63.16M shares derived: average of 2 quarters · filed 2022-02-10 | 62.89M shares derived: average of 3 quarters · filed 2022-02-10 | 62.78M shares 10-K · filed 2022-02-10 |
| 2021-09-30 | 62.96M shares 10-Q · filed 2021-11-05 | 62.65M shares derived: average of 2 quarters · filed 2021-11-05 | 62.59M shares 10-Q · filed 2021-11-05 | 62.38M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2021-06-30 | 62.34M shares 10-Q · filed 2021-08-06 | 62.40M shares 10-Q · filed 2021-08-06 | 62.18M shares derived: average of 3 quarters · filed 2022-05-05 | 56.75M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | 62.19M shares 10-Q · filed 2022-05-05 | 62.10M shares derived: average of 2 quarters · filed 2022-05-05 | 54.89M shares derived: average of 3 quarters · filed 2022-05-05 | 41.82M shares derived: average of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | 62.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | 51.24M shares derived: average of 2 quarters · filed 2022-02-10 | 35.03M shares derived: average of 3 quarters · filed 2022-02-10 | 26.90M shares 10-K · filed 2022-02-10 |
| 2020-09-30 | 40.47M shares 10-Q · filed 2021-11-05 | 21.55M shares derived: average of 2 quarters · filed 2021-11-05 | 15.20M shares 10-Q · filed 2021-11-05 | 11.78M shares derived: average of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | 2.63M shares 10-Q · filed 2021-08-06 | 2.42M shares 10-Q · filed 2021-08-06 | 2.22M shares derived: average of 3 quarters · filed 2021-08-06 | 2.03M shares derived: average of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | 2.22M shares 10-Q · filed 2021-05-06 | 2.02M shares derived: average of 2 quarters · filed 2021-05-06 | 1.84M shares derived: average of 3 quarters · filed 2021-05-06 | 1.64M shares derived: average of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | 1.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | 1.65M shares derived: average of 2 quarters · filed 2021-02-12 | 1.45M shares derived: average of 3 quarters · filed 2021-02-12 | 1.29M shares 10-K · filed 2021-02-12 |
| 2019-09-30 | 1.46M shares 10-Q · filed 2020-11-10 | 1.26M shares derived: average of 2 quarters · filed 2020-11-10 | 1.10M shares 10-Q · filed 2020-11-10 | |
| 2019-06-30 | 1.05M shares 10-Q · filed 2020-09-02 | 922.00K shares 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |